Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ATNM 
Actinium Pharmaceuticals Inc (ATNM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ATNM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5
1 Year Target Price $5
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.53% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 54.90M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 5 | Beta -0.53 | 52 Weeks Range 1.03 - 2.41 | Updated Date 08/28/2025 |
52 Weeks Range 1.03 - 2.41 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-26 | When - | Estimate -0.348 | Actual -0.22 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.18% | Return on Equity (TTM) -130.59% |
Valuation
Trailing PE - | Forward PE 6.84 | Enterprise Value -3733232 | Price to Sales(TTM) 652.71 |
Enterprise Value -3733232 | Price to Sales(TTM) 652.71 | ||
Enterprise Value to Revenue 1726.07 | Enterprise Value to EBITDA -3.62 | Shares Outstanding 31195900 | Shares Floating 30858663 |
Shares Outstanding 31195900 | Shares Floating 30858663 | ||
Percent Insiders 1.79 | Percent Institutions 21 |
Upturn AI SWOT
Actinium Pharmaceuticals Inc
Company Overview
History and Background
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative targeted therapies for advanced cancers. Founded in 2011, it aims to deliver potent and selective treatments through its Antibody RadioConjugates (ARCs) platform.
Core Business Areas
- Therapeutic Development: Actinium focuses on developing targeted radiotherapies that use antibodies to deliver radioisotopes directly to cancer cells, minimizing damage to healthy tissue.
Leadership and Structure
The leadership team comprises experienced executives in the biopharmaceutical industry. The organizational structure includes research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Iomab-B: Iomab-B (Bexarotene Iodine I 131) is Actinium's most advanced product candidate, intended as a conditioning regimen prior to hematopoietic stem cell transplant (HSCT) in patients with relapsed or refractory acute myeloid leukemia (r/r AML). There is no direct market share data available as the product is under development. Competitors include conditioning regimens using chemotherapy. There are a few other companies which are developing similar drug products, but they are not yet FDA approved.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense research and development, stringent regulatory requirements, and high competition. Targeted therapies are a growing segment.
Positioning
Actinium is positioned as a specialist in targeted radiotherapies, particularly focusing on hematological malignancies. Their competitive advantage lies in their ARC platform.
Total Addressable Market (TAM)
The TAM for targeted cancer therapies is substantial and growing. Actinium is positioned to capture a segment of the market for conditioning regimens for stem cell transplantation, which is a large potential market. The total market value is estimated to be over $30 billion.
Upturn SWOT Analysis
Strengths
- Proprietary ARC platform
- Targeted therapy approach
- Potential for improved efficacy and reduced toxicity compared to traditional therapies
- Experienced management team
Weaknesses
- Reliance on single product candidate (Iomab-B)
- High R&D costs
- Regulatory and clinical trial risks
- Currently generating minimal revenue
Opportunities
- Potential for label expansion of Iomab-B to other indications
- Partnerships and collaborations
- Advancements in radioisotope technology
- Growing demand for targeted cancer therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- BPMC
- CLVS
- SNY
Competitive Landscape
Actinium's competitive advantage lies in its proprietary ARC platform. However, it faces competition from larger pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is largely tied to the progression of their clinical trials.
Future Projections: Future growth is heavily dependent on the successful clinical trials of Iomab-B and regulatory approvals. Analyst estimates will vary based on these factors.
Recent Initiatives: Recent initiatives include ongoing clinical trials of Iomab-B and expanding the pipeline.
Summary
Actinium Pharmaceuticals is a clinical-stage company with a promising platform for targeted radiotherapies. The company's success hinges on the clinical trial outcomes of Iomab-B. While their ARC platform holds significant potential, they face numerous risks associated with clinical development and regulatory approval. They must carefully manage their cash burn rate, especially as they are generating minimal revenues.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Actinium Pharmaceuticals Inc. website
- SEC filings
- Financial news sources
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investing in Actinium Pharmaceuticals Inc. involves significant risks, including the risk of loss.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Actinium Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters New York, NY, United States | ||
IPO Launch date 2012-12-27 | Chairman & CEO Mr. Sandesh C. Seth M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 27 | Website https://www.actiniumpharma.com |
Full time employees 27 | Website https://www.actiniumpharma.com | ||
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.